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On the verge of entering the post-antibiotic era, numerous efforts are in place to
regain the waning charm of antibiotics which are proving ineffective against most
“Superbugs”. Engineered nanomaterials, especially gold nanoparticles (GNPs) capped
with antibacterial agents, are proving to be an effective and novel strategy against multidrug resistant (MDR) bacteria. In this study, we report a one-step synthesis of antibioticcapped GNPs (25 ± 5 nm) utilizing the combined reducing and capping ability of a
cephalosporin antibiotic, ceftazidime. No signs of aggregation or leaching of ceftazidime
from GNP surface was observed upon its storage. Antibacterial testing showed dosedependent broad spectrum activity of Cef-GNPs against both Gram-positive (S. bovis and
E. durans) and Gram-negative (P. aeruginosa and E. aerogenes) bacteria. A significant
reduction in the minimum inhibition concentration (MIC) of Cef-GNPs was observed as
compared to the ceftazidime by itself against Gram-negative bacteria. The MIC of CefGNPs were 0.1 mg mL-1 (P. aeruginosa and E. aerogenes) and 1.2 mg mL-1 (E. durans
and S. bovis). Cef-GNPs exerted bactericidal action on both P. aeruginosa and E. durans
by disrupting the cellular membrane resulting in leakage of cytoplasmic content and
death of bacterial cell. Our investigation and results provides an additional step in the
development of antibiotic capped GNP as potent next generation antibacterial agents.
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1. INTRODUCTION
Bacteria, the most primitive organisms, on earth have remained one of the greatest
fears of human beings. Until 1940’s, infections caused by pathogenic bacteria were
regarded as the major cause of deaths amongst humans.1 These tiny little organisms,
ubiquitous in nature, which can be seen only under super powerful microscopes, have
continued to be a topic of intensive scientific research all over the world. It is estimated
that over billions of distinct types of bacteria are always present on, in, and around us at
any moment of time. Among those, only a handful of bacteria are beneficial to mankind
in terms of health and economy since they are employed in a variety of industrial
processes such as fermentation to make a variety of food products (alcohol, dairy
products etc.), genetic engineering for a large scale production of recombinant drugs and
vaccines and so on.2–4 Unlike mammals, the exponential growth of bacteria is in number
rather than size with relatively a short generation period, thereby turning them into microfactories engaged in large-scale manufacturing of desired products.5 In addition, a huge
number of pathogenic bacteria are also known for causing mild to lethal infectious
diseases, necessitating medical intervention.6 Plants, animals and humans serve as the
prime targets of bacteria. Viruses are the only organisms that have the potential to infect a
bacterial cell. Bacteria are often classified by their shape, atmosphere and their structural
make up.7 One of the most striking features of bacteria is their structural make-up of
outer cell wall which is regarded as the main armor of bacteria. Bacteria, whose
cell/plasma membrane is covered by only a thick layer of peptidoglycan are called Grampositive and the ones with an additional lipoprotein layer surrounding the thin
peptidoglycan layer are known as Gram-negative bacteria.8 The Presence of an extra
1

layer in Gram-negative bacteria confers them more strength and resistance towards
hydrophobic drugs and biomolecules.
Human beings can become more prone to bacterial infections which are
aggravated by poor sanitary conditions and health habits. Infections are also observed
during surgical operations, organ transplantations and conditions of war milieu where the
open wounds serve as an entry-point for the bacteria into the body.9 To safeguard from
the ill effects of pathogenic bacteria, nature has provided the human body with a
protection mechanism called the immune system to kill all the foreign agents which are
not beneficial for our body. This system works as the first-line defense against all the
infections caused by pathogenic agents including bacteria. The immune system produces
different cells, with a primary function to recognize and kill foreign pathogens entering
the body. For most of the infections, the human body has natural immunity while for
other infections, the body acquires immunity after repeated exposure to the specific
antigens.10 Despite lacking a brain, bacteria seemed very clever as they continuously alter
their genetic make-up in order to become unrecognized and resistant to attack by immune
system and continue to spread its ill effects. This was one of the main reasons for a
humongous number of deaths among people during World War I and II due to the
unavailability of appropriate medication to treat bacterial infections. This period was
regarded as the pre-antibiotic era, one of the most dreadful eras in the history of
medicine.11 In 1928, a miracle happened when Sir Alexander Fleming, a biologist,
accidentally discovered penicillin from the mold penicillium notatum which inhibited the
growth of the staphylococcus colonies.12 Soon after the discovery, penicillin became the
world’s first antibiotic and thus was the dawn of the antibiotic era. The structure and
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function of penicillin were elucidated, resulting in discovery of other potent structurally
related classes of antibiotics which were used against a range of serious bacterial
infections.13 In a nutshell, all the classes of antibiotics either kill or inhibit bacteria by
four major mechanisms i.e. disrupting the cell wall, blocking the protein synthesis,
inhibiting the DNA replication, or by affecting important bacterial cellular processes.14
With the advent of antibiotics, the mortality rate due to bacterial infections dropped
drastically and the infections were very much under control.
Despite the fact medical practitioners were well aware of the capability of bacteria
to develop resistance, improper care and irrational use of antibiotics was practiced
worldwide which gradually enabled bacteria to develop defense mechanisms to render
the potent antibiotics ineffective.15–17 The bacteria which became resistant to the
antibiotics were called as resistant bacteria. This was a clear suggestion that the process
to downfall antibiotics was initiated in bacteria. From a single antibiotic, bacteria started
developing resistance towards different classes of antibiotics, making them more
powerful and difficult to treat. Such bacteria were grouped under a new class called
multi-drug resistant bacteria (MDR). Some of the common examples include Methicillinresistant Staphylococcus aureus (MRSA) USA 300, Escherichia coli ST131, Klebisella
ST258, Carbapenem-resistant Enterobacteriaceae etc. Resistance is not localized; instead
it is spreading worldwide as a result of gene transmission, poor sanitary conditions in
hospitals and communities in which people live, global travel, bioterrorism etc. This is
evident from multiple cases such as the spread of antibiotic-resistant gonorrhea to the
Philippines and USA from Vietnam where it was first emerged in 1967 and New Delhi
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metallo-beta-lactamase 1 (NDM-1), first discovered in 2008 in New Delhi is now a
global problem.17
Similar to conditions during the pre-antibiotic era, bacterial infections are now
regarded as one of the major health concerns all over the world.18–21 This concern relates
to the soaring increase in cases of bacterial resistance towards front-line antibiotics.
Bacteria which were once susceptible to an antibiotic, have now developed some kind of
defense mechanism making them invulnerable to the effects of antibiotic. Development
of resistance in bacteria is inevitable and occurs due to genetic manipulation. Among the
normal population of bacteria, some inherit resistant genes which make them survive the
attack from antibiotics. As a result, the resistant bacteria that survived multiply rapidly
and produce a large number of bacterial populations containing the antibiotic resistant
gene. Treating infections with sub-therapeutic concentrations of antibiotics serves as the
driving force for developing resistance in bacteria. The root of rapid development of
resistance in bacteria can be attributed to human activities which includes the irrational
and overuse of antibiotics in hospitals, farms, and communities.22 In under-developed and
developing countries, due to the exorbitant cost of consulting a doctor, self-medication
has been practiced for many decades. It has become a common practice to prescribe
antibiotics without any proper diagnosis when a person falls sick. Common people relate
all infections to bacteria ignoring the fact that the infection can also be caused by other
pathogenic microorganisms like viruses or fungi. Prescribing antibiotics for flu and other
infections which are caused by virus is still practiced in many parts of the world. 23
Antibiotics are also used abundantly in hospitals. Nearly 7.7 million pounds of antibiotics
are prescribed every year in United States.24 Use of antibiotics for preventing infections
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and improving the growth of farm animals is another growing concern which causes and
spreads the resistant bacterial strains among local community population.25,26 Until
recently, this problem was never taken seriously which made the antibiotic resistant
bacteria to become multi-drug resistant (MDR) bacteria thereby making it very difficult
to cure infections caused by such resistant bacteria.27 The first antibiotic to which bacteria
had gained resistance was penicillin in 1943. Over the years, various antibiotics such as
tetracycline, erythromycin, methicillin, vancomycin, and more. were identified to be no
longer effective against the bacteria against which it was potent before.28 Among the
various resistant bacteria, Entercoccus faecium, Staphylococcus aureus, Klebisella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter
species (known as “ESKAPE” organisms) are regarded as the most harmful of all.29
Today, MDR has become one of the most talked and researched topic in scientific world
with magazines and newspapers warning about a future without any effective antibiotic to
treat bacterial infections.26 Some authors have described antibiotic resistance as being ‘as
big a risk as terrorism’ whereas some author describes it as the ‘return of our old enemies
in an untreatable form’.30,31 This pandemic condition must be addressed immediately to
avoid the MDR bacteria becoming pan-drug resistant (PDR), making our arsenal of
antibiotics ineffective. It is very essential to take an action today in order to have cure
tomorrow. Some of the major modern achievements of medicine, such as organ
transplants, are at stake because they cause a high risk of post-operative infections which
would be untreatable and fatal in many cases. In a recent 114 page report from CDC, it
was estimated that more than 2,049,442 Americans fall sick due to antibiotic-resistant
bacterial infections, killing 23,000 people annually. The report also categorized harmful
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pathogens into different threat levels ranging from URGENT THREAT (C. difficile,
Carbapenem-resistant Enterobacteriaceae, Drug-resistant Neisseria gonorrhea),
SERIOUS THREAT (Multidrug-resistant Acinetobacter, Drug-resistant Campylobacter,
Fluconazole-resistant Candida (a fungus), Extended spectrum β-lactamase producing
Enterobacteriaceae (ESBLs) , Vancomycin-resistant Enterococcus (VRE), Multidrugresistant Pseudomonas aeruginosa, Drug-resistant Non-typhoidal Salmonella, Drugresistant Salmonella Typhi, Drug-resistant Shigella, Methicillin-resistant Staphylococcus
aureus (MRSA), Drug-resistant Streptococcus pneumoniae, Drug-resistant tuberculosis)
and CONCERNING THREAT (Vancomycin-resistant Staphylococcus aureus (VRSA),
Erythromycin-resistant Group A Streptococcus, Clindamycin-resistant Group B
Streptococcus).32 This report calls for an urgent effort to find novel approaches for novel
antibiotic research and mobilizing the development pipeline to prevent the world from
entering post-antibiotic era. Organizations like the WHO and the CDC have released
various reports and infographics to educate people about the need for antibiotic
stewardship for preventing the current situation getting worse. Well aware of the time and
capital involved in developing new drug moieties, the United States Food and Drug
Administration (US-FDA) introduced Generating Antibiotics Incentives Now (GAIN)
under food and safety act in 2012 with a goal to boost the novel antibacterial research in
pharmaceutical and research organizations.33,34 Under this program, the FDA assigns
Qualified Infectious Disease Product (QIDP) status to novel antibacterial and antifungal
drugs which are found effective against qualifying pathogens (ESKAPE organisms,
Clostridium difficicle etc.). QIDP drugs benefits from a quick review process and upon
approval get an additional 5 years of market exclusivity rights. So far, 46 investigational
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drugs have been assigned QIDP status by FDA.35 Recently, two of the QIDP status drugs,
namely Dalvance (Durata Therapeutics)36 and Sivextro (Cubist Pharmaceuticals)37 were
approved by the FDA for the treatment of infections caused by MRSA. New Drugs for
Bad Bugs (ND4BB), a part of Europe’s Innovative Medicines Initiative program
introduced their third project called ENABLE (European Gram-Negative Antibacterial
Engine) which fosters 13 countries and 32 partners to develop new antibacterial agents
against Gram-negative resistant bacteria.38,39 There is a great need in developing nextgeneration antibacterial agents active against Gram-negative bacterial infections. In
addition, funding organizations all over the world are financially supporting various
research facilities who are involved in developing alternative strategies against antibiotic
resistant bacteria. Recently, the National Institute of Health (NIH) awarded $2 million to
Duke University, USA to start a new clinical research network which focuses on
antibacterial resistance.40 Similarly, the U.S. military under the Defense Threat Reduction
Agency (DTRA) is funding a whopping $13.5 million on a research for developing new
systemic antibiotics to fight pathogens showing resistance to current antibiotics. The
research is being done jointly by Anacor Pharmaceuticals, Colorado State University
(CSU) and the University of California at Berkeley.41
In an alternate approach, ultra-fine particles in the size range of 1-100 nm called
nanoparticles are being widely exploited for their role as antibacterial agent.42
Nanotechnology has brought a revolution in science and technology. It has become one
of the most intense fields of scientific research, and has grown enormously over the last
ten years as evident from the soaring increase in the number of research articles published
on nanoparticles in various journals.43 Nanotechnology finds its applications in various
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fields such as medicine, electronics, biomaterials and energy storage production.44 The
variety of applications of nanoparticles are attributed to its unique physic-optical
properties which depend upon the size, shape, and environment in which they are
present.45 Nanoparticles can be easily manipulated into various sizes and shapes by
changing the concentration of reactants and experimental conditions. Nanoparticles have
a long history. They were used by various artisans for making bright colored glass cups
such as Lycurgus cup in Rome and more.46 Modern interest towards nanotechnology
started after a famous talk entitled “There’s a plenty room at the bottom” by physicist
Richard Feynman in 1959.47 Through the years, technology gave us different techniques
and methods to characterize and understand the nanoparticles in a much better way. In
general, the nanoparticles are classified into five distinct groups such as semiconductor
quantum dots, magnetic nanoparticles, polymeric particles, carbon based nanostructures
and metallic nanoparticles. Each class of nanoparticles has its unique features and
applications. For instance the semiconductor quantum dots are used for biological
labeling due to their size dependent fluorescence properties.48 Polymeric nanoparticles
such as dendrimers and liposomes acts as good carriers to load different hydrophobic and
hydrophilic drugs which can then be used for targeted drug delivery.49 Carbon based
nanoparticles are mostly used in batteries and as hydrogen storage.50 Most flexible among
all are the metal nanoparticles because of their synthetic control over size, shape,
composition, structure and assembly resulting in fine tunability of surface optical
properties. This project emphasizes metal nanoparticles. Gold nanoparticles (GNPs) due
to their non-toxic and biocompatibility nature have been widely researched for their use
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in biomedical applications involving targeted drug delivery, biological imaging, and
diagnostics44,51–53 (Figure 1).

Figure 1: Representative images showing advantages of using gold nanoparticles. (a)
Gold nanoparticles exhibit different colors owing to its unique optical properties known
as surface plasmon resonance. (b) Gold nanoparticles can be easily tuned to a variety of
sizes and shapes as required. (c) Gold nanoparticles can be decorated with various
functional groups as required for the specific application. (d) Gold nanoparticles are
known to be highly stable in nature. (e) Biocompatibility of gold nanoparticles is evident
from many marketed drug formulations involving gold for the medical treatment such as
rheumatoid arthritis. (f) Gold nanotechnology continues to attract researchers worldwide
as evident from more than 2000 patents registered in FY 2012.
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One of the emerging applications of GNPs is their use as nano-carriers for
improved antibacterial activity. There are many papers in the literature which show
enhanced antibacterial effect of either naked GNPs or antibiotic conjugated GNP’s.42,43
The methods used for the synthesis of GNPs in above studies involves the use of toxic
chemicals which can reduce and stabilize the ionic gold Au3+ to neutral gold atoms Au0
which aggregates resulting in GNPs (Figure 2(a)). Citrate, sodium borohydride,
hydroquinone and hydroxyl radicals are the common reducing agents used whereas
thiolates, amines, phosphanes, carbonyls, dendrimers and surfactants are used as
stabilizing agents. Lately, the use of all these chemicals have raised both biological and
environmental toxicity concerns, demanding a need for finding a cleaner and more green
method of synthesis for GNPs.54 In response to this, we have successfully developed and
patented (U.S. Patent No. 82576706) a unique method for the biofriendly synthesis of
GNPs wherein dextrose was used as both reducing and capping agent in a buffered
aqueous solution at moderate temperature to synthesize monodisperse, stable, watersoluble GNPs with significant yield.55 Due to structural resemblance of dextrose with
most of the commercial antibiotics, we hypothesized and successfully synthesized GNPs
using ampicillin as a reducing and capping agent to yield ampicillin capped GNPs (AmpGNPs) by a green process. Antibacterial testing revealed greater activity of Amp-GNPs
when compared to equivalent concentrations of free ampicillin. In order to make sure
ampicillin is not an isolated case, various other antibiotics are currently being studied for
enhanced antibacterial activity upon conjugating with GNPs. In the present study,
ceftazidime was used as the investigational antibiotic. Ceftazidime, a third generation
cephalosporin is widely used as a broad spectrum antibiotic for treating bacterial
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infections.56 It inhibits a step involved in the synthesis of the bacterial cell wall by
binding to penicillin binding proteins (PBP) which inhibits crosslinking within the cell
wall. The activity is due to the presence of a β-lactam ring. Ceftazidime is used
intravenously or intramuscularly to treat lower respiratory, urinary tract, joint, skin and
blood-stream infections. It is prescribed as a first-line drug for the treatment of
meliodosis. Ceftazidime is mostly used against infections caused by Gram-negative
bacteria. Ceftazidime is also listed in the WHO List of Essential Medicines.57 Currently,
ceftazidime is marketed with a brand name of Fortaz and Tazicef.58 Ceftazidime still
remains as the investigational drug for research against Gram-negative infections.
Recently, a ceftazidime/avibactam combination which is jointly researched by
AstraZeneca and Forest Laboratories Inc. against Complicated Intra-Abdominal
Infections (cIAI) and Complicated Urinary Tract Infections (cUTI) received QIDP status
from US-FDA.59 The drug combination is currently under phase III clinical trials.
Keeping all the above facts in mind, ceftazidime was selected to increase its efficacy
against Gram-negative bacterial infections. In terms of synthesis, the presence of
hydroxyl and carbonyl groups which can reduce ionic gold were hypothesized to lead to
GNP synthesis. People have written in the literature about the involvement of amine
groups in stabilizing gold nanoparticles.60 Since the ceftazidime structure contained
hydroxyl, carbonyl, and amine groups, we hypothesized the ability of ceftazidime to act
as dual agent (reducing and capping) for making antibiotic capped GNPs. The overall
objective of the study was to design and develop a unique therapeutic formulation
involving ceftazidime capped GNPs for enhanced antibacterial activity against normal
and resistant bacterial strains.
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The design of the study involved finding optimum concentration to synthesize
ceftazidime gold nanoparticles (Cef-GNPs) using a single step method followed by its
characterization using various analytical techniques to obtain morphological and
elemental properties of Cef-GNPs. The schematic involved in the synthesis of Cef-GNPs
is shown in Figure 2(b). In-vitro antibacterial efficiency of synthesized Cef-GNPs was
tested against Gram-positive and Gram-negative bacterial strains with a more emphasis
on Gram-negative bacteria. Antibacterial assays used for the study include bacterial
growth assay, spread plate assay, XTT assay, and propidium iodide assay. Efficiency of
Cef-GNPs was determined by comparing its MIC, obtained from the above assays with
the MIC of pure ceftazidime

12

Figure 2: Schematic showing the steps involved in synthesis of gold nanoparticles. (a)
Represents a conventional method of synthesis with the use of a reducing agent which
reduces ionic gold to neutral gold atoms followed by addition of capping agent which
stabilizes the gold aggregates to form nanoparticles. (b) Illustrates our single-step
biofriendly process for making gold nanoparticles using the dual reducing and capping
nature of the antibiotic, ceftazidime. (c) Represents the various stages involved in the
synthesis of gold nanoparticles, starting from nucleation which grows until stabilized by a
capping agent.
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2. MATERIALS AND METHODS
2.1. MATERIALS:

Reagent
Ceftazidime Hydrate
Glycerol
L.B Agar Media
L.B Media

Catalogue number
C3809
GX0190-6
240110
71753-6

Menandione

ME105

Petri Dishes
Potassium aurochlorate
Propidium Iodide
T.S Agar Media
T.S Media
XTT Salt
Sodium Chloride
Sodium dihydrogen
phosphate
Disodium hydrogen
phosphate

875713
450235
537059
236950
T0420
10060
3624-05

Company
Sigma Aldrich
EMD Chemicals
BD Company
Novagen
Spectrum
Chemicals
Fisher Brand
Sigma Aldrich
Calbiochem
BD Company
Teknova
Biotium
J.T. Baker

SX0711-1

EMD Chemicals

1.06573.0503

EMD Chemicals

Table 1: List of all the reagents or chemicals used for the study with their respective
catalogue number and manufacturing company
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Supply
Catalogue Number
96 well Microtiter Plates
25381-056
Ependorff’s – 1.5 mL
87003-294
Falcon tubes – 15 mL
89039-666
Falcon tubes – 50 mL
89004-364
Glass Culture tubes
14-961-27
Micropipette tips – 1-1000 µL
83007-382
Micropipette tips – 1-20 µL
53509-070
Micropipette tips – 1-200 µL
53503-606
Parafilm
PM-996
Spreaders
420201-786
TEM grids
0400-CU

Costar
VWR
VWR
VWR
Fisher brand
VWR
VWR
VWR
Bemis Flexible Packaging
VWR
Electron Microscopy Science

TEM Negative Films

Electron Microscopy Science

74100

Company

Table 2: List of all the supplies required for the study with their respective catalogue #
and manufacturing company
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Instrument
-80 C Freezer
Autoclave Machine
Bio Microtiter Plate Reader
Biological Safety Cabinet
Centrifuge
DLS
Excella 625 Shaking Incubator
Hitachi UV-Vis Spectrometer
JEOL SEM
JEOL TEM
Lyophlizer
Nanopure water machine
Perkin Elmer FTIR
Petri Plate Scanner

Use
Store bacterial stock culture
Sterilize solutions and supplies
Bacterial growth assay
Working with bacteria (aseptic conditions)
Concentrating gold nanoparticles
Particle size distribution
Bacterial and nanoparticle incubation
Optical absorption of nanoparticle solution
elemental composition of nanoparticles
Morphological characteristics of nanoparticles
Freeze drying of gold nanoparticles
Nano pure water (free from impurities)
Organic confirmation of nanoparticles
Counting colonies on petri plates

Probe Sonicator

Breaking the clusters and aggregates of nanoparticles

Refrigerator
TA Thermogravimetric
Analysis
VWR Incubator
VWR Magnetic Stirrer

Storing the solutions and reagents

o

Organic % determination on gold nanoparticles
Growth of bacteria on agar plates
Mixing and dissolving solutes in solution

Table 3: A detailed list of most of the instruments used for the study along with their
specific use.
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Bacterial strains

Remarks

Enterobacter
aerogenes
(ATCC # 13048)

 Gram –ve bacterium belonging enterobacteriaceae family*
 Bacilli (rod) shape bacteria with flagella
 Causes opportunistic infections
 Multi-resistant to antibiotics
* requires quick and urgent action according to CDC 2013
report

Pseudomonas
aeruginosa
(ATCC # 27853)

 Gram –ve bacterium belonging pseudomonadaceae family*
 Coccobacillus shape
 Causes healthcare associated infections
 Some strains are found to be pan-drug resistant
* possess serious concern and requires steps to prevent the
spread

Enterococcus
Durans
(ATCC # 6056)

 Gram +ve bacterium belonging enterococcaceae family*
 Coccus shape
 Major cause of urinary tract, bloodstream and surgical
infections
 Some strains show resistance to antibiotic of last resort,
vancomycin.
* possess serious concern and requires prompt action to prevent
the spread

Streptococcus
Bovis
(ATCC # 9809)

 Gram +ve bacterium belonging streptococcaceae family*
 Cocci shape, lactic acid bacterium
 Strains of Group A and B causes pharyngitis, necrotizing
fasciitis, rheumatic fever, meningitis, sepsis etc.
 Group A and B are proven resistant to clindamycin
* Streptococcus A and B group strains resistance against
macrolides is concerning and needs careful monitoring

Table 4: List of all bacterial strains with their ATCC number and characteristic features
used for the antibacterial assay
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2.2.

PREPARATION OF REAGENTS:

2.2.1. Wash protocol:
All the apparatus and containers were thoroughly rinsed and washed with soap
water, tap water and nanopure water and are allowed to air dry. The containers were then
sterilized in an autoclave machine at 121 oC for ~1 hour and stored until further use.
2.2.2. Preparation of sterilized nanopure water:
Following the wash protocol, roughly ~500 mL of nanopure water from the
nanopure machine was transferred into 1000 mL sterilized reagent bottle. The caps were
screwed loosely and the solution was autoclaved using the liquid cycle. Once the process
was finished, the caps were screwed tightly and stored in 2-8 oC until further use.
(Note: For all the liquid cycles, the volume of the solution must be half of the container
capacity)
2.2.3. Preparation of ceftazidime stock solution: (5 mM, 500 mL)
( )

Following the wash protocol, 1.365 g of ceftazidime hydrate (see Appendix A for
product specification) was weighed using microbalance and transferred into a 500 mL
reagent bottle. Around 250 mL of sterilized nanopure water was added to the flask and
the contents were thoroughly mixed using a magnetic stirrer until a homogenous solution
was obtained. The resulting solution was transferred into a 500 mL measuring cylinder
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and water was added to make up to the desired volume (500 mL). The solution was
transferred back into the reagent bottle and caps were screwed tightly. The bottle was
labelled appropriately and stored at 2-8 oC until further use.
2.2.4. Preparation of potassium gold (III) chloride (KAuCl4) stock solution: (132 mM,
50 mL)
( )

Following the wash protocol, 2.5 g of potassium gold (III) chloride was weighed
using the microbalance and transferred into a 100 mL reagent bottle. The solute was
dissolved by adding 50 mL of sterilized nanopure water to obtain a homogenous solution.
The bottle was labelled appropriately and stored at 2-8 oC until further use.
2.2.5. Preparation of L.B media: (1 Liter, 25g/L)
Following the wash protocol, 25 g of L.B media was accurately weighed using the
weighing balance and transferred into a 2000 mL reagent bottle. ~500 mL of sterilized
nanopure water was then added and the contents were mixed thoroughly using a magnetic
stirrer until all the contents are properly dissolved. The contents were then transferred
into a 1000 mL measuring cylinder and made up to the desired volume (1000 mL) using
sterilized nanopure water. The solution was retransferred into 2000 mL reagent bottle and
with the loosely screwed caps. The solution was sterilized and stored at 2-8 °C in
refrigerator until further use.
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2.2.6. Preparation of tryptic Soy (T.S) media: (1 Liter, 30g/L)
Following the wash protocol, 30 g of T.S media was accurately weighed using the
weighing balance and transferred into a 2000 mL reagent bottle. ~500 mL of sterilized
nanopure water was then added and the contents were mixed thoroughly using a magnetic
stirrer until all the contents are properly dissolved. The contents were then transferred
into a 1000 mL measuring cylinder and made up to the desired volume (1000 mL) using
sterilized nanopure water. The solution was retransferred into 2000 mL reagent bottle and
with the loosely screwed caps. The solution was sterilized and stored at 2-8 °C in
refrigerator until further use.
2.2.7. Preparation of L.B/T.S agar plates: (40 plates)
(Note: 25 mL of solution is required for each petri plate. Make sure to prepare extra in
case of any spills of improper pouring)
Following the wash protocol, 40g of L.B agar/ T.S agar was weighed and
transferred into a 2000 mL Erlenmayer flask. ~500 mL of sterilized nanopure water was
added and the contents were mixed thoroughly using magnetic stirrer until all the solute
was dissolved. The solution was transferred into a 1000 mL measuring cylinder and made
up the volume to the desired level (1000 mL) using sterilized nanopure water. The flask
was covered using two fold aluminum foils and sterilized in an autoclave using liquid
cycle. In the meantime, the disposable petri plates were UV-sterilized under a biological
safety cabinet. After the autoclaving was done*, 25 mL of the solution was poured using
a 50 mL falcon tube into each petri plate without forming bubbles. The plates were
allowed to solidify by keeping them half open in the hood. Once the plates were
solidified, the lid was covered and the petri plates were wrapped using parafilm all
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around the rim to avoid contamination. The plates were labelled appropriately and stored
at 2-8 oC in refrigerator until further use.
* Do not allow the autoclaved solution sit for a long time. The solidifying temperature for
the agar solution is ~36 oC
2.2.8. Preparation of 10X phosphate buffer saline (PBS) (1 liter):
Following the wash protocol, 6.084 g of sodium dihydrogen phosphate, 57.28 g of
disodium hydrogen phosphate and 87.66 g of sodium chloride was accurately weighed
and transferred into a 2000 mL reagent bottle. ~800 mL of sterilized nanopure water was
then added and the contents were mixed until all the solutes were uniformly dissolved.
The volume was made up to 1000 mL using sterilized nanopure water and the pH was
adjusted to ~7.2 using a pH meter. The caps were loosely screwed and the solution was
sterilized using liquid cycle. After the autoclaving was done, the caps were tightly
screwed and labelled appropriately. The solution was stored at room temperature until
further use.
2.2.9. Preparation of XTT solution: (1mg/mL, 30 mL)
Following the wash protocol 30 mg of XTT dye was weighed and transferred into
100 mL conical flask. 30 mL of 7.2 pH phosphate buffer saline (PBS) was added and
contents were mixed vigorously. The flask was covered with two folds aluminum foils
and sterilized using liquid cycle. After the autoclaving was done, 1mL of the solution was
aliquot into each 1.5 mL ependorff’s under aseptic conditions. The ependorff’s were
labelled appropriately and stored in -4 oC refrigerator until further use.
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2.2.10. Preparation of menadione solution: (10mM, 50 mL)
( )

Following the wash protocol, 86 mg of menadione was accurately weighed and
transferred into a 100 mL reagent bottle. 50 ml of acetone was added and mixed
thoroughly. The bottle was labelled appropriately and stored it in -4 oC until further use.
2.2.11. Preparation of TEM copper grids:
The 400 mesh size copper grids were washed and cleaned by dipping them into
1M HCL, followed by water with intermittent drying using a filter paper. Finally, the
grids were dipped into a solution of acetone and dried by dabbing on a filter paper. The
formvar coating solution was assembled which includes the glass burette attached to a
stand. The burette was washed by running a wash solution through it. The formvar
solution was poured into the burette with the knob in close position. A clean glass slide
was kept into the formvar solution for roughly 30 seconds after which the solution was
drained by turning the knob. The glass slide was then removed from the apparatus using
tweezers and placed it in a closed jar for drying. The edges of the slide were scrapped
using a razor in order to release the film coating from the slide smoothly. With the help of
a jar filled with water up to the rim, the film coating was gently released from the slide by
immersing it into the water slowly. The light sides of the washed grids were deposited
onto the silver/gold interface of the floating film. With the help of parafilm, the grids
were carefully removed and cut using tweezers and placed it in a petri dish containing
filter paper. Once dried, the grids were used immediately for TEM analysis.
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2.2.12. Preparation of Cef-GNPs stock solution: (1mg/mL, 10 mL)
For the antibacterial assays, a stock solution of Cef-GNPs was prepared by
accurately weighing 10 mg of Cef-GNPs lyophilized powder and adding it into 15 mL
sterilized falcon tube. 10 mL of sterilized nanopure water was added and the solution was
mixed vigorously using a vortex. For monodisperse GNPs, the solution was sonicated
using a probe sonicator at 45 % amplitude for 10 minutes with pulse on for 10 sec and
pulse off for 5 sec. The solution was labelled and stored at 2-8 °C until further use.
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2.3. EXPERIMENTAL METHODS:
2.3.1. Synthesis of ceftazidime gold nanoparticles (Cef-GNPs):
Unlike the conventional method which uses various harmful chemical agents to
reduce and stabilize GNPs, we designed and developed a self-patented synthesis method
for making monodisperse GNPs whose size can be easily varied by changing the
concentration of either nucleating or stabilizing agent. For the synthesis, a range of
concentrations in different ratios were tried to determine the optimum concentration
which yielded the GNPs of desired morphology. Some of the properties which were taken
into consideration for determining the optimum concentration include yield,
monodispersity, the concentration of reactants, as well as the size and shape of GNPs.
The fabrication process was a unique, single step method which followed most of the 12
principles of green chemistry. Multiple concentrations involving ceftazidime (0.5, 1, 3
and 5 mM) and potassium aurochlorate (50, 100, 200 and 300 ppm) were screened by
monitoring their color and UV-Vis spectrum. Among all the concentrations, 5 mM of
ceftazidime with 200 ppm of gold salt resulted in nanoparticles with high yield and
desired morphology. For a typical synthesis (120 mL) of ceftazidime gold nanoparticles
(Cef-GNPs), 12 mL of 5 mM pre-prepared ceftazidime stock solution was mixed with
108 mL of sterilized nanopure water in a 250 mL Erlen Mayer flask. To the mixture, 480
µL of pre-prepared gold salt solution was added and mixed using a vortex. 30 mL of
solution was aliquot in four 50 mL falcon tubes respectively. Test tubes were labelled
appropriately and incubated at 37 °C for 12 hours with a shaking speed of 150 rpm.
Shaking was very essential to prevent the aggregation of nanoparticles. After the
incubation time, the contents of each falcon tube were transferred into a clean and
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sterilized oakridge tubes (centrifuge tubes) and the solution was centrifuged at 15,000
rpm for 15 minutes using F21 rotor in Sorval RC 5B centrifuge. After the centrifugation
was done, the supernatant was carefully discarded using a pipette and was replaced with
equal volume of sterilized nanopure water. The tubes were centrifuged again as
mentioned above. The process was repeated thrice to ensure no unreacted reagents
(antibiotic or gold salt) was present in the resulting nanoparticle. After the last cycle, the
solution was concentrated to a final volume of 12 mL using a microcentrifuge and stored
in a 50 mL falcon tube at 2-8 oC until further use.
2.3.2. Determining the yield of ceftazidime gold nanoparticles (Cef-GNPs):
One of the major factor is any manufacture process is the yield obtained from the
reaction. Yield of the product helps in evaluating the efficiency of synthesis process and
also gives an insight about the extent of reactants that are getting used up in the reaction.
The yields of synthesized Cef-GNPs were also evaluated using freeze drying process. For
each batch of 120 mL, the concentrated solution obtained after repeated washing and
centrifugation was added into aluminum cups, freezed under liquid nitrogen and kept for
drying at 30 °C overnight under vacuum. The cups were covered with a thin cloth to
avoid loss of product during the drying process. The lyophilized powder of Cef-GNPs
was carefully extracted from the cups and weighed using a highly precise analytical
balance. The process was repeated for multiple batches of synthesis to determine the
yield and percentage variation.
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2.3.3. Characterization of ceftazidime gold nanoparticles:
Before the synthesized Cef-GNPs were evaluated for antibacterial activity, it was
necessary to confirm the formation of GNPs as well as the presence of antibiotic on its
surface. For this purpose, a range of spectroscopic and microscopic techniques were used
to characterize Cef-GNPs.61,62
UV-Vis Spectroscopy
One of the inherent features of gold nanoparticles is its ability to show a plasmon
resonance peak in the visible region due to its surface properties. GNPs show a
characteristic UV-Vis peak which is dependent on the size, shape, and nature of
environment in which the GNPs are present. Therefore, UV-Vis was used as a qualitative
tool to evaluate the formation of GNPs. For the analysis, a dilute solution of synthesized
Cef-GNPs was sonicated at 45 % amplitude for 5 minutes. A UV-Vis absorption
spectrum of the resulting solution was recorded from 400-900 nm using Hitachi U-3900
with a scan speed of 600 nm/min and slit width of 5 nm.
Dynamic Light Scattering (DLS)
This is a simple technique to determine the particle size distribution of
synthesized GNPs. The principle behind analysis is the scattering of light emitted from
laser by the suspension of GNPs which are in constant motion called the Brownian
motion. The scattered light from the sample falls onto the detector which is processed by
the software to give the average size distribution and polydispersity of the sample. For
the analysis, 1 mL of diluted sample of Cef-GNPs was probe sonicated and analyzed
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using Zetasizer Nano S, Malvern Instruments Ltd. at 25 °C with a scattering angle of 90°.
Sampling was done in triplicate with 13 runs in each measurement.
Transmission Electron Microscope (TEM)
In order to observe things which are really small, super powerful high resolution
microscopes are required. TEM analysis of Cef-GNPs was performed to determine its
morphological characteristics. A 10 µL of dilute sample of Cef-GNPs was loaded on 400mesh formavar coated copper grids. Excess liquid was wiped off by dabbing the grid onto
a filter paper. The grids were air-dried at room temperature and imaged on a JEOL-TEM.
The sample was viewed at different magnifications on a phosphorous screen by shooting
120 kV of electron beam. Images of the desired region of the grid were taken using the
in-built camera which was later processed, developed, and scanned for future reference.
The scale marker (size of the grid X magnification = size on negative film) of 100 nm
(obtained from the ruler) was placed on the TEM negative film.
Scanning Electron Microscope- Energy Dispersive Spectroscopy (SEM-EDS)
Elemental composition of Cef-GNPs was determined using low resolution SEMEDS technique. Our primary interest was to check the presence of organic elements like
carbon (C) which confirms the presence of ceftazidime bounded onto GNPs surface. For
the analysis, 50 µL of Cef-GNPs solution was pipetted on a clean aluminum stub and airdried at room temperature. The stubs were then imaged on a JEOL JSM-5400 LV
microscope with IXRF system. The samples were thoroughly washed with sterilized
nanopure water to get pure GNPs, free from any traces of impurities. Using the IXRF
system, the SEM images were exported into the software and elemental composition was
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determined at different spots on the images. The elements and their corresponding weight
were recorded.
Fourier Transform Infrared Spectroscopy (FTIR)
One of the widely used techniques by organic chemists is FTIR which gives an
insight about the nature of functional groups present in an unknown compound. FTIR
was used as a qualitative technique to determine the presence of organic ceftazidime on
GNPs, as well as to determine the changes in the IR peak of functional group which helps
in understanding the bonding interactions between ceftazidime and GNP. For the
analysis, first a background (air) spectrum was taken to avoid any unwanted signals. For
the sample spectrum ~5 mg of lyophilized powder of Cef-GNPs was placed on the highly
sensitive Perkin-Elmer Spectrum 100 FT-IR spectrophotometer fitted with a universal
ATR accessory. Force was applied using the pressure gauge onto the sample to ensure
better contact with the IR rays. IR spectrum was run from 4000-650 cm-1 at a resolution
of 4 cm-1 using the Spectrum One software. 128 scans were taken for each spectrum. The
process was repeated for pure ceftazidime and the IR spectrums were overlapped for data
interpretation.
Thermogravimetric Analysis (TGA)
After confirming the presence of organic content onto GNPs surface, the amount
of ceftazidime present onto GNPs was qualitatively determined by studying thermal
decomposition using TA Q5000 TGA technique. Roughly ~7 mg lyophilized sample of
Cef-GNPs was placed on a platinum pan and heated from room temperature to 650 °C
under nitrogen gas flow followed by air from 650 °C to 850 °C. TGA was also performed
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under total air flow from room temperature to 850 °C. A thermogram of decomposition
and decrease in the weight percentage over temperature of organic ceftazidime was
obtained using universal TA software. Analysis is done multiple times to get an average
composition of organic weight percentage. TGA of pure ceftazidime was also done to
compare the weight loss pattern of ceftazidime upon capping onto GNP surface. (see
Appendix B for detailed methodology)
2.3.4. Assessing the stability of Cef-GNPs:
One of the prime factors that is considered for any drug formulation is its storage
stability under normal conditions. A formulation which is stable for a long period of time
is generally preferred over less-stable formulations. In that context, the stability of CefGNPs was studied over a fixed period of time. Any change in the morphology of GNPs,
directly affects its UV-Vis peak. For that reason, UV-Vis spectrum of two Cef-GNPs
samples, one kept at room temperature and another in refrigerator were monitored
periodically (0 days, 30 days, and 60 days). The data from this study helps in
understanding the stability of Cef-GNPs at room temperature and under proper storage
conditions. In addition, binding interactions of organic ceftazidime with GNP surface was
also evaluated over a period of 60 days by comparing the TGA thermogram of
lyophilized Cef-GNPs samples maintained at room temperature and in the refrigerator.
2.3.5. Evaluating antibacterial activity of Cef-GNPs:
Preparation of glycerol stock of bacterial strains:
Fresh glycerol stock of bacterial strains was prepared as and when required.
Firstly, a preculture or a small scale culture of the desired bacterial strain was grown by
adding 200 µL of bacterial stock into 10 mL of nutrient media (L.B/T.S) taken in a 50
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mL sterilized falcon tube. The solution was mixed and incubated at 37 °C, 150 rpm for
12 hours in a shaking incubator. After the incubation period, the optical density (O.D) of
the culture was measured using Spectronic-20 spectrometer. When the O.D of culture
reached ~1.2, 1.5 mL (10 %) of viscous glycerol was added into the falcon tube and
mixed properly. 250 µL of resulting solution was aliquot into 1.5 mL sterilized
ependorff’s, labelled and stored in -80 °C freezer until further use. The entire process was
done in a biological safety cabinet in order to ensure aseptic conditions.
Preparation of preculture of bacterial strains:
A small culture of desired bacterial strain referred to as preculture was prepared
by the following method. Thaw an ependorff, stored in -80 °C freezer containing the
glycerol stock of desired bacterial strain. Add 10 mL of nutrient media (L.B/T.S) into a
50 mL sterilized falcon tube and transfer 250 µL from glycerol stock into the falcon tube.
Screw the cap tightly and incubate the mixture at 37 °C, 150 rpm for 12-14 hours in a
shaking incubator until the O.D of the culture reaches to ~1.2. Table 5 lists the preculture
conditions required for the strains that are used for the antibacterial assays.
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Bacterial Strain

Enterobacter aerogenes
Enterococcus durans
Pseudomonas aeruginosa
Streptococcus bovis

Staining
Gramnegative
Grampositive
Gramnegative
Grampositive

Glycerol
Stock for
10 mL
preculture

Nutrient
media
used

200 µL

L.B broth

200 µL

T.S broth

200 µL

L.B broth

200 µL

T. S. broth

Incubation conditions
37 °C, 150 rpm, 12-14 hrs
37 °C, 150 rpm, 12-14 hrs
37 °C, 150 rpm, 12-14 hrs
37 °C, 150 rpm, 12-14 hrs

Table 5: Incubation conditions required for the preparation of preculture of various
bacterial strains under study.
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Ennumeration of bacterial colony forming units (CFU/mL):
For all antibacterial assays, the concentration of bacteria was maintained uniform
at 1 X 106 CFU per mL of solution. In order to obtain the desired CFU for different
strains, serial dilution was performed and the resulting solution was plated onto agar
plates to get countable colonies (300-400) as shown in Figure 3. Using the serial dilution
and number of colonies on agar plate, number of colony forming units was calculated
using the below formula (see Appendix C more images of petri plates)
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Figure 3: Schematic illustrating the serial dilution process involved in the calculation of
bacterial CFU/mL
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Bacterial Growth Curve:
Growth of bacteria follows a definite pattern starting from a lag phase,
exponential phase, stationary phase and death phase. In the lag phase, the bacterial cells
get accustomed to the new nutrient conditions. In the exponential or growth phase, the
bacterial cell starts multiplying by binary fission and grows in number. In the stationary
phase, the growth of new bacterial cells becomes equal to the death of old cells. Finally in
the death phase, due to unavailability of nutrients and accumulation of waste, the
bacterial cells start dying. Therefore by measuring the growth of bacterial cells in
presence of various concentrations of Cef-GNPs, its efficiency in killing/inhibiting
bacteria can be evaluated. The primary goal of the assay was to determine the lowest
concentration of Cef-GNPs required to inhibit the growth of bacterial cells which is more
often called the minimum inhibition concentration (MIC). The assay was performed in a
96-well microtiter plate. The perimeter of the plate was filled with nanopure water to
prevent evaporation of sample during incubation. Each plate contained three rows of
sample (Cef-GNPs + nutrient media + bacterial cells), positive control (nutrient media +
bacterial cells) and negative control (Cef GNPs + nutrient media). For the sample, 100
µL of sterilized nanopure water was added into all the working wells. Double the
concentration of the desired highest concentration of Cef-GNPs was prepared from the
Cef-GNPs stock and concentrated down to a final volume of 100 µL which was then
added into the first sample well. A serial dilution was performed by transferring 100 µL
from first well into the succeeding well. Serial dilution was continued until the last well
and 100 µL from the last well was discarded. The above steps were repeated for all the
sample and blank rows. For the control well, 100 µL of sterilized water was added
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instead of Cef-GNPs. To all the sample and control wells, 150 µL of bacterial solution
having 1 X 106 CFU/ml was added. In the blank well, 150 µL of nutrient media was
added. (see Appendix D for microtiter plate design) The micotiter plate was covered with
the lid and incubated at 37 °C and 150 rpm. Absorbance of the solution was measured at
600 nm at every 2 hours for a period of 12 hours. Using the data from excel, a graph of
absorbance vs. time was plotted for different concentrations of Cef-GNPs. The above
procedure was repeated for all the bacterial strains and also for the pure ceftazidime drug.
Spread plate assay61:
As an extension to the bacterial growth assay, a small volume of solution from the
sample well used in the growth assay was diluted appropriately and spread onto a L.B/
T.S agar plate respectively using a sterilized glass spreader. The plates were then kept in
the incubator for the colonies to grow for 12-16 hours at 37 °C. After the incubation time,
the numbers of colonies in each plate were counted to determine the bactericidal
concentration. In general, the MIC concentration of Cef-GNPs against a particular
bacterial strain won’t show growth of any viable colonies after the incubation period. In a
way, the assay was used as a confirmatory test to the bacterial growth assay.
XTT assay63,64:
It is a colorimetric method for determining MIC of antibiotic formulation. It is
generally considered as more convenient and robust than the conventional plate count
method which is associated with many drawbacks such as cell clumping, giving an
inaccurate number of colonies resulting in improper results. This technique is more
accurate as it measures the viable cell count by measuring the reducing activity of the
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cells. Respiration occurs in all live/active cells through a reducing environment involving
electron transport system. In this method, an artificial tetrazolium dye (yellow colored) is
reduced to formazan (orange color product) by active cells which has a characteristic
absorbance at 492 nm. Since formazan is a color product, it can be quantitatively
determined using visible spectrometer which gives the number of viable cells. To
amplify the results of XTT, an activator is added called menadione. Therefore formation
of orange color indicated growth of bacterial cells and MIC is taken as the lowest
concentration which does not show formation of orange color formazan product. For the
assay, the bacterial cells were grown in a 96-well microtiter plate against various
concentrations of Cef-GNPs as mentioned in the above assay. After the 12 hour
incubation period, 50 µL of XTT stock (995 µL of XTT solution + 5µL of menadione
solution) was added to the entire working wells and the plate was covered with an
aluminum foil and incubated in dark for more 2 hours. After 2 hours of incubation,
absorbance of the plate was read at 492 nm. Using the excel data; a graph of XTT
absorbance vs. concentration of Cef-GNPs was plotted. The assay was done for all the
bacterial strains.
2.3.6.

Visualizing mechanism of bactericidal action of Cef-GNPs

Propidium Iodide (PI) Assay62:
PI was used to determine the antibacterial mechanism of MIC of Cef-GNPs
obtained from the growth assays. PI is a red-fluorescent staining dye which has high
affinity towards bacterial DNA. Due to its inability to permeate live cells, it can be used
in detecting the dead cells in a bacterial population. For the assay, one Gram-positive and
Gram-negative bacterial strain was incubated in presence of the MIC of Cef-GNPs for ~
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12 hours followed by which the samples were centrifuged (6000 rpm, 3 min) and washed
multiple times with pH ~7.2 phosphate buffer saline (PBS). Samples were further
incubated with 5 µL of PI (10 mM) for 30 minutes in dark. After incubation, unbound PI
was removed by washing the sample with PBS and 10 µL of the resulting suspension was
sandwiched on a glass slide covered with cover slip. Sample was viewed using Leica
fluorescence microscope. A sample of bacteria without Cef-GNPs was taken as control.
Numbers of permeable cells (showing red fluorescence) were counted by taking average
from three individual measurements and a graph was plotted in comparison to control for
respective bacterial strains.
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3. RESULTS AND DISCUSSION
3.1. Synthesis of ceftazidime gold nanoparticles (Cef-GNPs):
Gold nanoparticles are formed when Au3+ of KAuCl4 is reduced to Au0 in
presence of a reducing agent. Au0 being unstable, settles down in the course of time and
clusters with other Au0 atoms to form gold colloids/aggregates. In order to prevent further
aggregation of gold colloids beyond the nanoscale, a secondary agent is added which
stabilizes the nucleation of gold aggregates by capping its surface resulting in gold
nanoparticles. To synthesized GNPs are then functionalized with desired ligands based on
the application of interest. In the conventional methods of GNP synthesis, a range of
reducing agents such as sodium borohydride, sodium citrate, superhydride, hexadecyl
aniline were used whereas thiols, xanthates, disulfides, trithiols, phosphine, amine,
carboxylate ligands, iodine, acetone etc. were used as stabilizing agents. Looking at the
wide biological applications of GNPs, assessing the risk and toxicity of GNPs
synthesized using the above methods to the environment and other living organisms has
become a crucial topic of research. The use of organic chemicals and solvents in the
above chemical synthetic methods might prove to be toxic to the environment and
biological species. In response, there is a great interest in finding alternate methods which
are safer and biofriendly. Biocomponents derived from plant and animals are being
widely studied for their role in biosynthesis of GNPs.43,65 The advantages of using
biological sources include cost-effective process and non-toxicity but practically it
becomes quite a laborious process due to the presence of many impurities for which
additional purification steps must be performed to obtain pure GNPs. In addition, large
scale production requires a huge biomass which must be acquired and processed to be
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used in the synthesis process. As an alternate approach, use of substances which can acts
as ‘dual agents’ in reducing and concomitant capping of GNP are gaining a lot of focus.
Advantages of using dual agents include single step process, they are cost-effective, they
can have applicability for large-scale production, they avoid waste and byproducts, and
are non-laborious, as well as others. In our previous studies, we had developed a green
and biofriendly process for making monodispersed GNPs using dextrose as dual agent.
Dextrose was efficient in reducing gold ions due to the presence of electron rich hydroxyl
groups which can readily be oxidized. Extending the scope of our method, we have been
trying a range of antibiotics which can be used as dual agents to form antibiotic capped
gold nanoparticles, a formulation that can potentiate the activity of functionalized
antibiotic against various bacterial strains.
The molecular structure of ceftazidime contains many electron rich groups such
as amine, hydroxyl and carbonyl which can donate their electrons in reducing the ionic
gold to form GNPs. It is very crucial for ceftazidime to have enough electrons that can be
used to reduce gold ions (Au3+) derived from KAuCl4 to form Au0 atoms. The exact
mechanism for reducing and simultaneous capping of gold by antibiotic is still under
debate. Therefore, one of the preliminary steps in our study was to determine the
optimum concentration of ceftazidime (reducing/capping agent) and gold salt (nucleating
agent) required which was achieved by trying different combinations. Small scale
synthesis involving a combination of ceftazidime (0.5, 1, 3 and 5 mM) and gold (50, 100,
200 and 300 ppm) were tried by incubating the mixture in a culture tube at 37 °C for 12
hours with a shaking speed of 150 rpm. The solution was kept on continuous stirring to
prevent aggregation of GNPs. The synthesis protocol was adhered to the ‘12 principles of
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Green Chemistry’. The color of solution and its respective UV peak were used as an
indicator for determining the nature of GNPs. Color of tubes after 12 hours of incubation
for different concentration is shown in Figure 4. Detailed information about the different
trials and their respective UV observation is listed in Table 6. Among all the
concentrations, 0.5 mM ceftazidime with 200 ppm of gold salt gave a high yield of GNPs
with a significant UV peak and thus was selected as the concentration required for all the
further synthesis. For a typical synthesis, an aqueous solution of 0.5 mM of ceftazidime is
mixed with 200 ppm of aqueous solution gold salt and the resulting mixture is incubated
at 37 °C for 12 hours at a shaking speed of 150 rpm. The color of solution changes from
colorless to light brownish upon addition of gold salt to ceftazidime solution. An
indication of the formation of GNPs was from the color change of the reaction mixture
from light brownish to clear pink after 12 hours of incubation. After multiple washings,
the resulting solution containing Cef-GNPs was concentrated and subjected to
lyophlization to determine the yield. The average yield of Cef-GNPs from multiple
batches of 120 mL was found to be 15 ± 0.63 mg.
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Figure 4: Image showing color of test tubes for various concentrations of ceftazidime
and gold after 12 hours of incubation. (a) Ceftazidime concentration of 0.5 mM with 50,
100 and 200 ppm of gold. Ceftazidime concentration of 1 mM (b), 3 mM (c) and 5mM
(d) with 100, 200 and 300 ppm.
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Concentration of
Reactants
Ceftazid Gold
ime
salt
300
5 mM
ppm

Observation
0 hour

12 hour

24 hour

Brown;
clear

Brown;
clear
Light
yellowish;
clear

Brown;
clear
Light
yellowish;
clear

Yellowish;
clear

Yellowish;
clear

Greenish;
clear
More
brownish;
clear
Light
brownish;
clear
Settled;
pinkish
Light pink;
settled
Light
brownish;
clear

Greenish;
clear
More
brownish;
clear
Light
brownish;
clear
Settled;
pinkish
Light pink;
settled
Light
brownish;
clear

Pink; clear

Pink; clear

Light pink;
clear
Transparent;
clear

Light pink;
clear
Transparent;
clear

5 mM

200
ppm

5 mM

100
ppm

3 mM

300
ppm

Light
yellowish;
clear
Light
brown; clear

3 mM

200
ppm

Light
brown; clear

3 mM

100
ppm

Light
brown; clear

300
ppm
200
ppm

Brown;
turbid
Brown;
clear

100
ppm

Brown;
clear

200
ppm
100
ppm
50
ppm

Brown;
turbid
Brown;
clear
Brown;
clear

1 mM
1 mM
1 mM

0.5 mM
0.5 mM
0.5 mM

Less brown;
clear

Yield/
supernatant

UV
peak

Good;
Yellowish

535

Moderate;
yellowish

No
yield

No yield

No
yield

Good;
yellowish

615

Moderate;
yellowish

532

No yield

No
yield

High; clear

562

Moderate;
clear

555

Less;
yellowish

531

Moderate;
clear
Good; light
yellowish
Very low;
light yellowish

548
556
525

Table 6: A list showing the color and UV observation of all the different combinations of
ceftazidime and gold tried for the synthesis of Cef-GNPs
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3.2. Characterization of Ceftazidime Gold Nanoparticles (Cef-GNPs):
UV-Vis spectroscopy remains one of the most quick and reliable tools for
identifying the formation of GNPs. This is due to the fact that GNPs possess an inherent
property called surface plasmon resonance (SPR), showing an intense peak absorption in
the visible region, sensitive to size, shape, aggregation, and nature of solvent. UV-Vis
spectra of resulting Cef-GNPs suspension showed peak absorption at 548 nm,
characteristic for spherical GNPs (Figure 5(a)). The peak was sharp with no formation of
humps, indicating the Cef-GNPs to be monodispersed and non-aggregated.
To validate the UV-Vis data, samples were observed under high resolution TEM
for morphological characterization. The image captured at 100 kX magnification showed
well-dispersed spherical particles in the size range of 25 ± 5 nm (Figure 5(b)). The
images clearly support our hypothesis as proposed in the synthesis mechanism. TEM
images of other concentrations were also observed which showed signs of low yield,
large size and aggregation. With the TEM data, the concentration chosen for the synthesis
yielded the best nanoparticles among all the other concentrations. (see Appendix E for
additional TEM image)
To further corroborate the results, dynamic light scattering (DLS) was performed
on the dilute suspension of Cef-GNPs at a scattering angle of 90°. DLS is another widely
used characterization technique for nanoparticles where a light emitted by a laser source
is passed through the nanoparticles which are in constant motion in solution. Intensity of
scattered light from nanoparticles is plotted as a function of time and the hydrodynamic
size of particles is determined. DLS is highly sensitive and the size of nanoparticle is
influenced by the substances (ligand) adsorbed on the surface of nanoparticle unlike the
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case in microscopic techniques which measures only the metallic core of nanoparticle. As
a result, the resulting size from DLS generally differs marginally from the TEM or UV
data.66 DLS analysis of Cef-GNPs showed a sharp peak with an average size distribution
of 45 ± 15 nm (Figure 5(c)).
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Figure 5: Representative images showing morphological characterization of Cef-GNPs.
(a) UV-Vis spectra of Cef-GNPs showing a strong absorption peak at 548 nm which is
characteristic of spherical GNPs. The figure in the inset represents color change from
light brownish to pink indicating formation of GNPs. (b) TEM photograph showing
formation of well-dispersed spherical GNPs in the size range of 25 ± 5 nm by reducing
KAuCl4 using an cephalosporin antibiotic, ceftazidime. (c) Plot showing average particle
size distribution obtained using dynamic light scattering (DLS) at a scattering angle of
90°.
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FTIR67 was also used as a qualitative tool to determine the changes in the peaks of
functional groups of ceftazidime upon its capping onto GNP surface. For the analysis, IR
spectrums of pure ceftazidime and Cef-GNPs were recorded and the spectrums were
overlapped as shown in Figure 6. Spectrum of Cef-GNPs had similar peaks as observed
in pure ceftazidime, thereby confirming it’s capping on GNP surface. The peaks in the IR
spectrum were as follows: 1680-1630 cm-1: C=O axial deformation of amide group,
1350-1300 cm-1: axial deformation from C-N, 1600-1475 cm-1: aromatic ring C=C
deformation, 1750-1725 cm-1: C=O stretching of carboxylic functional group, 3660-3250
cm-1: N-H axial deformation respectively. A closer look on the peaks of Cef-GNPs,
shows the peak indicating N-H deformation were gone or not significant, indicating their
involvement in the reduction and capping of ceftazidime with nanoparticles. Minor
stretching’s for carbonyl were also observed indicating their role in the synthesis of CefGNPs. The peaks responsible for the β-lactam ring were undisturbed, thereby preserving
the inherent bactericidal action of the antibiotic.
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Figure 6: An overlay IR spectrum of Cef-GNPs and pure ceftazidime. The IR peak of
Cef-GNPs closely resembled with that of pure ceftazidime. The N-H stretching in the
region of 3660-3250 cm-1 as evident in pure ceftazidime was absent or insignificant in
Cef-GNPs, indicating their involvement in the reduction of ionic gold. Minor stretching
was also observed for carbonyl group in the region 1750-1725 cm-1. The figure in the
inset represents the molecular structure of ceftazidime with major functional groups
which has strong IR peaks. The peaks responsible for the β-lactam ring (highlighted
section) were undisturbed, thereby preserving the inherent bactericidal action of
antibiotic.
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SEM analysis of Cef-GNPs revealed the formation of spherical GNPs (Figure
7(a) inset). Quantitative analysis of the surface elemental composition was determined
from the SEM preparation using EDX spectroscopy. The EDX spectrum of Cef-GNPs
synthesized using ceftazidime is shown in Figure 7(a). Vertical axis represents the
number of x-ray counts while the horizontal axis shows the energy (keV). Peaks at
binding energy of 0.285, 0.395, 0.535 and 2.135 keV corresponded to carbon (C),
nitrogen (N), oxygen (O) and gold (Au) respectively. EDX analysis showed the presence
of ~87% of reduced gold and ~5% of carbon, ~2 % of nitrogen and ~3 % of oxygen
respectively. Gold peak in the EDX analysis was from the GNPs while the carbon,
oxygen and nitrogen peak were attributed to the organic molecule, ceftazidime present on
the surface of GNPs. SEM-EDX results confirmed the presence and capping of
ceftazidime on the surface of GNP.
Quantitative determination of the weight content of the organic ceftazidime was
determined using thermogravimetric analysis (TGA) as shown in Figure 7(b). As a
control, free ceftazidime was also subjected to TGA analysis. From the thermogram, two
major weight loss steps were observed for both Cef-GNPs and free ceftazidime. The first
weight loss was due to the moisture loss till ~150 °C and the second weight loss from 200
°C to 850 °C was attributed to the decomposition of organic ligand (ceftazidime). For the
Cef-GNPs, the peak became horizontal after a weight loss of 35.61 % representing the
amount of ceftazidime bonded on GNP surface. In comparison, a total weight loss of
88.54 % was observed for the free ceftazidime. Total decomposition of pure ceftazidime
wasn’t observed due the presence of 10 % of sodium carbonate (Na2CO3) in the
ceftazidime drug as stabilizer. Sodium carbonate being an ionic compound has a high
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melting point which is beyond 850 °C. As a result, only 90 % weight loss was observed
which represented the ceftazidime present in the drug. From the TGA study, a high
percentage of organic ceftazidime was found on the GNP surface which confirms all the
above observations obtained from TEM, SEM, UV-Vis, DLS and FTIR data (see
Appendix F for TGA data of Cef-GNPs taken under air flow).
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Figure 7: Represents qualitative and quantitative analysis of organic ligand (ceftazidime)
on GNP surface. (a) Energy dispersive spectroscopy (EDS) spectra of Cef-GNPs showing
the presence of elemental peaks for carbon (C), nitrogen (N), oxygen (O) and gold (Au)
constituting ~ 5%, 2 %, 3 % and ~85% respectively. Figure in the inset represents
scanning electron microscope (SEM) image of Cef-GNPs suspension layered on an
aluminum stub obtained at an accelerating voltage of 20 keV with 5kx magnification.
SEM-EDX results confirmed the presence and capping of ceftazidime on the surface of
GNP. (b) Thermogravimetric analysis (TGA) thermogram showing weight loss of
organic matter for ceftazidime (˗˗˗˗) and Cef-GNPs (- - -) respectively. The samples were
heated from room temperature to 650 °C at a rate of 10 °Cmin-1 under nitrogen flow
followed by heating till 850 °C under air. A total weight loss of 35.61

0.25 % in Cef-

GNPs indicated the amount of ceftazidime bounded on GNP surface. Total
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decomposition of pure ceftazidime was not observed due to the presence of 10 % of ionic
sodium carbonate which has high melting point.
Change in the UV-Vis spectrum of Cef-GNPs was monitored to determine its
storage stability. After recording the UV spectrum of two samples of freshly synthesized
Cef-GNPs, one sample was kept at room-temperature while the other was kept in
refrigerator. UV-Vis spectra of both the samples were recorded after 30 days and 60 days
respectively. An overlay plot of UV-Vis spectra’s of two samples taken at 0, 30 and 60
days is shown in (Figure 8 (a and b)). The peak absorption was found to be 548 ± 2 nm
(refrigerator sample) and 549 ± 2 nm (room-temperature sample) respectively. No
significant change in the peak intensity or SPR wavelength for both the samples
suggested the storage stability of Cef-GNPs. A slight decrease in the intensity could be
attributed to the handling error while performing the analysis.
In addition to UV, TGA analysis was also performed to determine the change in
the percentage weight loss upon storage. Two samples, one at room temperature and
other in refrigerator were subjected for TGA after 60 days of storage. An overlay plot of
thermogram for both samples showed a weight loss of 36.22 ± 0.2 which was near
identical to the weight loss obtained for the fresh Cef-GNPs sample (Figure 8(c)). The
TGA data shows no leaching of ceftazidime from GNP surface upon its storage.
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Figure 8: Illustrates assessment of stability of Cef-GNPs. (a) An overlay of UV-Vis
spectrum of 0, 30 and 60 days old sample of Cef-GNPs suspension stored at room
temperature showing no major shift in the intensity and peak absorption value. The
average peak absorption value was found to be 549 ± 2 nm. (b) An overlay of UV-Vis
spectrum of 0, 30 and 60 days old sample of Cef-GNPs suspension stored in refrigerator
showing no major shift in the intensity and peak absorption value. The average peak
absorption value was found to be 548 ± 2 nm. From the UV results, no signs of leaching
or aggregation were observed. (c) TGA curves comparing the change in the percentage
of organic material for 60-days old Cef-GNPs kept in refrigerator and room temperature.
The % weight loss for both samples was found similar (36.22 ± 0.85 %). The weight loss
was almost equal to the weight loss of fresh Cef-GNPs.
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3.3.

Evaluation of In-vitro Antibacterial Activity:

3.3.1. Cef-GNPs against Gram-negative bacteria:
The overriding purpose of the study was to determine the efficiency of
synthesized Cef-GNPs in combating bacteria as compared to the pure ceftazidime. The
primary focus was the activity against Gram-negative bacteria (P. aeruginosa and E.
aerogenes) due to the wide use of ceftazidime in the treatment of such bacterial
infections. Conventional antibacterial testing methods such as bacterial growth assay and
spread plate assay were used with minor modifications. Growths of fresh cultures of
respective bacterial strain were monitored periodically for 12 hours in presence of
different concentrations (0.06, 0.012, 0.025, 0.05, 0.10 and 0.20 mg mL-1) of Cef-GNPs
by measuring the optical density (OD) at 600 nm, which shows minimal absorption from
nutrient media and GNPs. The lowest concentration of Cef-GNPs which showed 90 %
inhibition of bacterial growth was taken as the minimum inhibition concentration (MIC).
From the results of bacterial growth assay, dose-dependent bacteriostatic action of CefGNPs was observed against both Gram-negative bacterial strains. The MIC of Cef-GNPs
was found to be 0.05 mg mL-1 against P. aeruginosa and E. aerogenes. Furthermore
antibacterial testing was performed by counting the viable bacterial cells grown on a solid
agar plate. Overnight cultures of bacteria grown in presence of different concentration of
Cef-GNPs were diluted and spread onto solid agar plate. The petri plates were incubated
at 37 °C for 14-18 hours. Samples of bacteria grown in absence of nanoparticles were
taken as control. From the spread plate results, gradual decrease in the number of viable
bacterial cells with increasing nanoparticle concentration were observed confirming the
bactericidal activity of Cef-GNPs. The concentration that yielded an insignificant number
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of viable bacterial colonies was taken as the MIC. The MIC results from spread plate
assay against Gram-negative bacteria were in compliance with the growth assay. The
number of viable cells of P. aeruginosa and E. aerogenes at the MIC of Cef-GNPs were
less than 5 % as compared to the control. To check the precision of results, a separate
colorimetric assay was also performed using a detecting agent XTT, which shows a
change in color from yellowish to orange (formazan product) in presence of living
bacterial cells. The lowest concentration in the well which showed no orange color
formation or 90 % reduction in the absorption at 492 nm (characteristic for XTT) was
taken as the MIC. The results of XTT against P. aeruginosa and E. aerogenes were in
compliance with the previous assays. The results of all antibacterial assays against P.
aeruginosa and E. aerogenes are shown in Figure 9 and Figure 10 respectively. To
determine the aggregation effect of Cef-GNPs with nutrient media, various concentration
of Cef-GNPs were incubated with L.B. and T.S broth individually and absorbance was
checked at 600 nm periodically (see Appendix G for graph)
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Figure 9: Illustrates dose dependent inhibition by Cef-GNPs against Gram-negative, P.
aeruginosa. (a) Monitoring the growth of P. aeruginosa in presence of increasing
concentrations of Cef-GNPs by measuring the OD at 600 nm every 3 hours for a period
of 12 hours. MIC of Cef-GNPs was found to be 0.1 mg mL-1. (b) Visualizing the growth
of P. aeruginosa on a solid agar plate in presence of MIC of Cef-GNPs obtained from the
growth assay. Untreated sample of bacteria was used as control. (c) P. aeruginosa
susceptibility testing against varying concentrations of Cef-GNPs by colorimetric assay
which involves reduction of a yellow tetrazolium salt (XTT) to orange formazan product
by metabolic active bacterial cells. The MIC (0.1 mg mL-1) was similar to the MIC
obtained using spread plate and growth assay. (d) A plot of corresponding XTT assay
obtained by measuring OD of wells at 492 nm, which shows peak absorption for orange
formazan derivative. Wells with 90 % reduction in OD492 nm compared to positive control
or no orange color formation was taken as MIC.
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Figure 10: Illustrates dose dependent inhibition by Cef-GNPs against Gram-negative, E.
aerogenes. (a) Monitoring the growth of E. aerogenes in presence of increasing
concentrations of Cef-GNPs by measuring the OD at 600 nm every 3 hours for a period
of 12 hours. MIC of Cef-GNPs was found to be 0.1 mg mL-1. (b) Visualizing the growth
of E. aerogenes on a solid agar plate in presence of MIC of Cef-GNPs obtained from the
growth assay. Untreated sample of bacteria was used as control. (c) E. aerogenes
susceptibility testing against varying concentrations of Cef-GNPs by colorimetric assay
which involves reduction of a yellow tetrazolium salt (XTT) to orange formazan product
by metabolic active bacterial cells. The MIC (0.1 mg mL-1) was similar to the MIC
obtained using spread plate and growth assay. (d) A plot of corresponding XTT assay
obtained by measuring OD of wells at 492 nm, which shows peak absorption for orange
formazan derivative. Wells with 90 % reduction in OD492 nm compared to positive control
or no orange color formation was taken as MIC.
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3.3.2. Cef-GNPs against Gram-positive bacteria:
For evaluating the broad-spectrum activity of synthesized Cef-GNPs, additional
antibacterial testing was performed against Gram-positive bacteria (S. bovis and E.
durans). Growths of fresh cultures of respective bacterial strain were monitored
periodically for 12 hours in presence of different concentrations (0.125, 0.250, 0.50, 1
and 1.2 mg mL-1) of Cef-GNPs by measuring the optical density (OD) at 600 nm, which
shows minimal absorption from nutrient media and GNPs. From the results, the CefGNPs showed a dose-dependent inhibition of bacterial growth but the concentration
required was significantly high. The MIC was found to be 1.2 mg mL-1 against S. bovis
and E. durans. Further antibacterial assays were not performed as the concentration
obtained from growth assay was too high. The results of growth assay against Grampositive bacteria are shown in Figure 11. In general, third generation cephalosporin are
found to be more potent against Gram-negative as compared to Gram-positive
microorganisms. This could be the reason for high MIC of Cef-GNPs against S. bovis and
E. durans. Nevertheless, Cef-GNPs were found to have broad-spectrum activity with a
higher potential against Gram-negative bacteria.
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Figure 11: Illustrates dose dependent inhibition by Cef-GNPs against Gram-positive
bacteria. (a) Monitoring the growth of S. bovis in presence of increasing concentrations
of Cef-GNPs by measuring the OD at 600 nm every 3 hours for a period of 12 hours.
MIC of Cef-GNPs was found to be 1.2 mg mL-1. (b) Monitoring the growth of E. durans
in presence of increasing concentrations of Cef-GNPs by measuring the OD at 600 nm
every 3 hours for a period of 12 hours. MIC of Cef-GNPs was found to be 1.2 mg mL-1.
From the above results, Cef-GNPs were proved to have broad-spectrum antibacterial
activity.
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In order to evaluate the efficacy of Cef-GNPs over pure ceftazidime, bacterial
growth assays were carried out against all the above bacterial strains in presence of pure
ceftazidime. The MIC of pure ceftazidime for Gram-negative (P. aeruginosa and E.
aerogenes) was found to be 0.35 mg mL-1 while that for Gram-positive (S. bovis and E.
durans) was found to be 1.0 mg mL-1. A plot of MIC comparison for Cef-GNPs and
ceftazidime by itself against all the bacterial strains under test is shown in Figure 12.
From the above results, it was evident that Cef-GNPs were more potent than ceftazidime
by itself against Gram-negative bacteria.
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Figure 12: Illustrates a plot of MIC comparison for pure ceftazidime and bound
ceftazidime (Cef-GNPs) against multiple strains of Gram-positive and Gram-negative
bacteria. The MIC of Cef-GNPs (0.1 mg mL-1) was found to be significantly lower than
the free ceftazidime (0.35 mg mL-1) against Gram-negative bacteria which proves its invitro efficiency as a potent antibacterial agent. As far as Gram-positive bacteria, the CefGNPs activity was almost similar to that of pure ceftazidime. If the actual dose of
ceftazidime present on GNP surface is taken into consideration, the MIC values are much
lower for Cef-GNPs as compared to ceftazidime by itself.
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3.4.

Visualizing Bacterial Permeability of Cef-GNPs68:
To confirm the bacterial membrane permeability of Cef-GNPs, propidium iodide

(PI) assay was used to determine the ratio of viable/dead cells. The assay was performed
against one Gram-negative (P. aeruginosa) and one Gram-positive (E. durans) bacteria.
For the assay, overnight samples of bacteria grown in presence of Cef-GNPs were
incubated with PI and observed under Leica fluorescence microscope. PI shows red
fluorescence after binding with the nucleic acids. Untreated samples of bacteria with
nanoparticles were taken as control. The results showed ~90 % permeability of PI into
bacterial cells against both P. aeruginosa and E. durans at a Cef-GNP concentration of
0.1 mg mL-1 and 1.2 mg mL-1 respectively (Figure 13). Permeability of PI suggests
formation of perforations in presence of Cef-GNPs. In contrast, the control sample didn’t
show any significant fluorescence as the bacterial cells remained intact, restricting the PI
influx into the cytoplasm. The above data confirms the bactericidal action of Cef-GNPs
as evident from the disruption of cell membrane which resulted in leakage of cell
contents including nucleic acids.
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Figure 13: Illustrates fluorescence images of Cef-GNPs induced cell membrane
permeability using propidium iodide (PI) dye which has strong binding affinity towards
nucleic acids. Upper panel represents Gram-negative, P. aeruginosa and lower panel
represents Gram-positive, E. durans. (a) For each image, the left half represents
differential interference contrast mode, while the right half represents the corresponding
fluorescence image. Untreated samples of respective bacteria with Cef-GNPs were taken
as control. (b) Represents a plot showing percentage permeability of P. aeruginosa and E.
durans bacterial cells in presence (MIC) and absence (control) of Cef-GNPs.
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4. CONCLUSION
A novel and efficient antibacterial strategy which involves the use of the
commercial antibiotic ceftazidime capped onto the surface of gold nanoparticle was
prepared in a single-step process without using any toxic chemical agents. The overall
objective of the study was to develop a novel antibacterial formulation to fight against
bacterial strains. Monodisperse, spherical GNPs in the size range of 25 ± 5 nm were
formed which showed great storage stability as conferred from UV and TGA analysis.
According to the FTIR data, the interaction of ceftazidime with GNP surface was
attributed to the amine and carbonyl groups. A high percentage of ceftazidime was found
to be capped on GNP surface. Antibacterial testing showed dose-dependent bactericidal
activity against both Gram-negative and Gram-positive bacteria. The MIC of Cef-GNPs
against Gram-negative bacteria (P. aeruginosa and E. aerogenes) was found to be 0.1 mg
mL-1 while that for Gram-positive (S. bovis and E. durans) was found to be 1.2 mg mL-1.
In comparison, the MIC of pure ceftazidime against Gram-negative was 0.35 mg mL-1
while for Gram-positive was 1.0 mg mL-1. A significant decrease in the MIC of CefGNPs as compared to ceftazidime by itself proved its greater efficiency in combating
Gram-negative bacteria. Cef-GNPs were found to have high bacterial permeability
thereby disrupting cellular environment which causes death of bacterial cell. In
conclusion, we report a simple bio-friendly process using combined reducing and capping
ability of antibiotic to make stable and efficient GNPs which holds a promising future for
its clinical use as antibacterial agent. Future work is necessary to elucidate the in-vivo
antibacterial activity of Cef-GNPs against resistant bacterial strains using animal models
and also to assess the cytotoxicity of GNPs which could facilitate its biomedical use.
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6. APPENDIX
6.1. Appendix A: Product Specification of Ceftazidime Hydrate:

Figure 14: Molecular Structure of Ceftazidime hydrate

Product Name:

Ceftazidime hydrate – 90.0-105.0 %

Formula:

C22H22N6O7S2 · xH2O

Formula Weight:

546.58 g/mol

Storage Temperature:

2 - 8 °C

Appearance (Color):

White to off-White

Appearance (Form):

Powder

Solubility (Color):

Colorless to faint Yellow

Solubility (Turbidity):

Clear

Moisture content:

≤ 15.0 %

Sodium carbonate content: 9 – 11 %
Assay (Dry Basis):

90.0 – 105.0 %
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6.2. Appendix B: Step-wise process involved in TGA analysis of Cef-GNPs:

Figure 15: A detailed step-wise process involved in the TGA analysis of Cef-GNPs.
Method A refers to the analysis in presence of nitrogen and air while Method B refers to
analysis under total air flow.

70

6.3. Appendix C: Petri Plates Images for Calculating Bacterial CFU/mL:
Gram-negative bacteria:

Figure 16: (a) Images of petri plates showing viable bacterial cells after respective
dilution of the preculture. The dilution of 10-7 resulted in countable colonies in the range
of 300-400 colonies. (b) Shows the dilution factor required for the antibacterial assays
against Gram-negative bacteria to yield 1 X 106 CFU/mL in the resulting solution.
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Gram-positive bacteria:

Figure 17: (a) Images of petri plates showing viable bacterial cells after respective
dilution of the preculture. The dilution of 10-7 resulted in countable colonies in the range
of 300-400 colonies. (b) Shows the dilution factor required for the antibacterial assays
against Gram-positive bacteria to yield 1 X 106 CFU/mL in the resulting solution.
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6.4. Appendix D: Microtiter plate design for bacterial growth assay and XTT
assay:

Figure 18: Design of microtiter plate for antibacterial assays. The perimeter wells are
filled with water to avoid sample evaporation. Sample wells are B, C and D from 2 to 7
which contain 100 µL of drug + 150 µL of bacterial culture (1X 106 CFUmL-1). The
highest concentration of drug is added in B2 and is serially diluted in the succeeding
wells. Blank wells are F, G from 2 to 7 which contains same concentration of drug as in
sample wells with 150 µL of nutrient media instead of bacteria. This is used to remove
background absorbance from drug and media. Control well is D and E 10 which contains
bacteria, used to monitor the growth of bacteria.
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6.5. Appendix E: Additional Transmission Electron Microscopy (TEM) image
of Cef-GNPs:

Figure 19: TEM photograph showing formation of well-dispersed spherical GNPs in the
size range of 25 ± 5 nm by reducing KAuCl4 using a cephalosporin antibiotic,
ceftazidime.
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6.6. Appendix F: Thermogravimetric analysis (TGA) of Cef-GNPs under air
flow:

Figure 20: Thermogravimetric analysis (TGA) thermogram showing weight loss of
organic matter for ceftazidime (---) and Cef-GNPs (- - -) respectively. The samples were
heated from room temperature to 850 °C at a rate of 10 °Cmin-1 under air flow. A total
weight loss of 35.38

0.35 % in Cef-GNPs indicated the amount of ceftazidime bounded

on GNP surface. Total decomposition of pure ceftazidime was not observed due to
presence of 10 % of ionic sodium carbonate which has high melting point. The data was
similar to the one obtained using nitrogen as gas.
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6.7. Appendix G: Interaction of nutrient media with Cef-GNPs:

Figure 21: (a) Interaction of different concentration of Cef-GNPs with Luria Broth media
which was the nutrient media used for Gram-negative bacteria. (b) Interaction of different
concentration of Cef-GNPs with Tryptic Soy media which was the nutrient media used
for Gram-positive bacteria
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7. ABBREVIATIONS
°C
L

Degree Celsius
Microliter

CDC

Centers for Disease Control and Prevention

Cef-GNPs

Ceftazidime-Gold Nanoparticles

CFU

Colony Forming Unit

DLS

Dynamic Light Scattering

EDS

Energy Dispersive X-Ray Spectroscopy

FDA

Food and Drugs Administration

FTIR

Fourier Transform Infrared Spectrometer

g

Gram

GNP

Gold Nanoparticles

hr

Hours

IR

Infrared

L.B

Luria Broth

MDR

Multi-Drug Resistant

Mg

Milligram

MIC

Minimum Inhibition Concentration

mL

Milliliter

mM

Millimolar

nm

Nanometer

OD

Optical Density

QIDP

Qualified Infectious Drug Product

SEM

Scanning Electron Microscope

SPR

Surface Plasmon Resonance

T.S

Tryptic Soy

TEM

Transmission Electron Microscope
77

TGA

Thermogravimetric Analysis

US

United States

UV-Vis

Ultraviolet-Visible

WHO

World Health Organization

XTT

(2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5Carboxanilide)

λmax

Peak Absorption
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